In New Iteration, Sequenom Is Genotyping Again, Aiming for Fine Maps, Partnerships, and Diagnostics | GenomeWeb

As it struggles to emerge from 2003's ill-fated foray into drug discovery, Sequenom last week announced its new identity.

Harry Stylli, the San Diego, Calif.-based firm's new CEO, said in a conference call that the company will lay off about 30 percent of its workforce, cut costs, and focus its efforts on its core research market. All the while, Sequenom is going to be searching for partners in research and product development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.